| Title |
Cell Cycle Regulation and Melanoma
|
|---|---|
| Published in |
Current Oncology Reports, April 2016
|
| DOI | 10.1007/s11912-016-0524-y |
| Pubmed ID | |
| Authors |
Wen Xu, Grant McArthur |
| Abstract |
Dysregulation of cell cycle control is a hallmark of melanomagenesis. Agents targeting the G1-S and G2-M checkpoints, as well as direct anti-mitotic agents, have all shown promising preclinical activity in melanoma. However, in vivo, standalone single agents targeting cell cycle regulation have only demonstrated modest efficacy in unselected patients. The advent of specific CDK 4/6 inhibitors targeting the G1-S transition, with an improved therapeutic index, is a significant step forward. Potential synergy exists with the combination of CDK4/6 inhibitors with existing therapies targeting the MAPK pathway, particularly in subsets of metastatic melanomas such as NRAS and BRAF mutants. This reviews summaries of the latest developments in both preclinical and clinical data with cell cycle-targeted therapies in melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Portugal | 1 | 1% |
| Poland | 1 | 1% |
| Unknown | 84 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 16% |
| Student > Ph. D. Student | 12 | 14% |
| Researcher | 8 | 9% |
| Student > Master | 5 | 6% |
| Other | 4 | 5% |
| Other | 18 | 21% |
| Unknown | 26 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 15 | 17% |
| Agricultural and Biological Sciences | 14 | 16% |
| Medicine and Dentistry | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Unspecified | 4 | 5% |
| Other | 11 | 13% |
| Unknown | 29 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2021.
All research outputs
#6,974,497
of 22,867,327 outputs
Outputs from Current Oncology Reports
#280
of 881 outputs
Outputs of similar age
#98,560
of 299,001 outputs
Outputs of similar age from Current Oncology Reports
#6
of 18 outputs
Altmetric has tracked 22,867,327 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,001 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.